2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1475

Does Skin Gene Expression Profile Predict Response to Imatinib?
Abstract Number: 2470

Does Structural Progression of Knee Osteoarthritis Measured with Magnetic Resonance Imaging or Radiography Predict Knee Replacement? – Data From the Osteoarthritis Initiative
Abstract Number: 728

Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Abstract Number: 799

Does Unpredictable Intermittent Knee Pain Limit Functional Ability and Walking Frequency in Knee OA?
Abstract Number: 2632

Doing Is Believing: Health Beliefs Before and After an Exercised-Based Rehabilitation Programme for Chronic Knee Pain
Abstract Number: 474

Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses
Abstract Number: 1365

Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Abstract Number: 1496

Downregulated Expression of Metallothionein Genes in Response to the Gadolinium Contrast Agent Omniscan in Normal Human Differentiated Macrophages and Dermal Fibroblasts
Abstract Number: 463

Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
Abstract Number: 1830

Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Abstract Number: 2460

Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome
Abstract Number: 1782

Dual Effects of Soluble FasL and Membrane Bound FasL On Fibroblast-Like Synoviocytes Cells (FLS) From Rheumatoid Arthritis (RA) Patients
Abstract Number: 1784

Dual Function of Interleukin-33 in Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis
Abstract Number: 154

Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods
Abstract Number: 481

Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].